FR2675694A1 - Systeme d'apport osteogenique pour facteurs de croissance morphogenetiques et procede pour preparer un tel systeme. - Google Patents
Systeme d'apport osteogenique pour facteurs de croissance morphogenetiques et procede pour preparer un tel systeme. Download PDFInfo
- Publication number
- FR2675694A1 FR2675694A1 FR9205249A FR9205249A FR2675694A1 FR 2675694 A1 FR2675694 A1 FR 2675694A1 FR 9205249 A FR9205249 A FR 9205249A FR 9205249 A FR9205249 A FR 9205249A FR 2675694 A1 FR2675694 A1 FR 2675694A1
- Authority
- FR
- France
- Prior art keywords
- biologically active
- delivery system
- bone
- porous
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000001002 morphogenetic effect Effects 0.000 title claims abstract description 9
- 230000002188 osteogenic effect Effects 0.000 title claims description 22
- 239000003102 growth factor Substances 0.000 title claims description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 38
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 38
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 16
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 11
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 11
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 11
- 239000003463 adsorbent Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 241000288906 Primates Species 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 8
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 claims description 6
- 102000008138 Bone Morphogenetic Protein 3 Human genes 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000012010 growth Effects 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 241001504519 Papio ursinus Species 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 230000011164 ossification Effects 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000002805 bone matrix Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000005377 adsorption chromatography Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 235000014653 Carica parviflora Nutrition 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000282520 Papio Species 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000243321 Cnidaria Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 241000204400 Goniopora Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/901—Method of manufacturing prosthetic device
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/915—Method or apparatus for preparing biological material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA913225 | 1991-04-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2675694A1 true FR2675694A1 (fr) | 1992-10-30 |
| FR2675694B1 FR2675694B1 (enExample) | 1995-05-24 |
Family
ID=25580652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9205249A Granted FR2675694A1 (fr) | 1991-04-29 | 1992-04-29 | Systeme d'apport osteogenique pour facteurs de croissance morphogenetiques et procede pour preparer un tel systeme. |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US5443531A (enExample) |
| DE (1) | DE4214117A1 (enExample) |
| FR (1) | FR2675694A1 (enExample) |
| GB (1) | GB2255907B (enExample) |
| ZA (1) | ZA923086B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0616814A1 (en) * | 1993-03-26 | 1994-09-28 | Bristol-Myers Squibb Company | Compositions for controlled release of biologically active TGF - beta |
| US8663337B2 (en) | 2007-06-18 | 2014-03-04 | Zimmer, Inc. | Process for forming a ceramic layer |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2551185C (en) | 1994-03-28 | 2007-10-30 | Sdgi Holdings, Inc. | Apparatus and method for anterior spinal stabilization |
| US5817327A (en) * | 1994-07-27 | 1998-10-06 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
| US5591453A (en) * | 1994-07-27 | 1997-01-07 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
| US6352972B1 (en) * | 1995-06-06 | 2002-03-05 | Marcel E. Nimni | Bone morphogenetic proteins and their use in bone growth |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US7175336B2 (en) * | 2001-01-26 | 2007-02-13 | Depuy Acromed, Inc. | Graft delivery system |
| JP2005521633A (ja) * | 2001-09-24 | 2005-07-21 | ベリーゲン アーゲー | 自己由来成長因子のカクテル組成物、生産方法および使用 |
| US7718616B2 (en) * | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| US8613938B2 (en) | 2010-11-15 | 2013-12-24 | Zimmer Orthobiologics, Inc. | Bone void fillers |
| WO2016044072A1 (en) | 2014-09-18 | 2016-03-24 | Mayo Foundation For Medical Education And Research | Soft tissue cutting device and methods of use |
| US10864055B2 (en) | 2017-10-13 | 2020-12-15 | Sonex Health, Inc. | Tray for a soft tissue cutting device and methods of use |
| US11937845B2 (en) | 2019-01-11 | 2024-03-26 | Mayo Foundation For Medical Education And Research | Micro-invasive surgical device and methods of use |
| EP3975889B1 (en) | 2019-05-29 | 2024-10-16 | Mayo Foundation for Medical Education and Research | Micro-invasive surgical device and methods of use |
| US12004767B2 (en) | 2021-01-08 | 2024-06-11 | Sonex Health, Inc. | Surgical cutting device for ultrasonic guided soft tissue surgery |
| USD989961S1 (en) | 2021-04-30 | 2023-06-20 | Sonex Health, Inc. | Soft tissue cutting device |
| US12251122B2 (en) | 2021-04-30 | 2025-03-18 | Sonex Health, Inc. | Cutting device for trigger finger and other soft tissues |
| WO2024044237A1 (en) | 2022-08-25 | 2024-02-29 | Sonex Health, Inc. | De quervain's treatment device |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4627982A (en) * | 1984-07-16 | 1986-12-09 | Collagen Corporation | Partially purified bone-inducing factor |
| EP0271668A1 (de) * | 1986-10-22 | 1988-06-22 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Wachstumstimulierendes Material, Herstellungsverfahren und therapeutische Zusammensetzung |
| WO1989010409A1 (en) * | 1988-04-08 | 1989-11-02 | Genetics Institute, Inc. | Bone and cartilage inductive compositions |
| WO1990003733A1 (en) * | 1988-10-11 | 1990-04-19 | International Genetic Engineering, Inc. | Osteogenic factors |
| WO1990011366A1 (en) * | 1989-03-28 | 1990-10-04 | Genetics Institute, Inc. | Osteoinductive compositions |
| US7720174B2 (en) * | 2001-12-21 | 2010-05-18 | Digital Fountain, Inc. | Multi-stage code generator and decoder for communication systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3929971A (en) * | 1973-03-30 | 1975-12-30 | Research Corp | Porous biomaterials and method of making same |
| US4294753A (en) * | 1980-08-04 | 1981-10-13 | The Regents Of The University Of California | Bone morphogenetic protein process |
| US4546500A (en) * | 1981-05-08 | 1985-10-15 | Massachusetts Institute Of Technology | Fabrication of living blood vessels and glandular tissues |
| US4596574A (en) * | 1984-05-14 | 1986-06-24 | The Regents Of The University Of California | Biodegradable porous ceramic delivery system for bone morphogenetic protein |
| NL8501769A (nl) * | 1984-10-02 | 1986-05-01 | Imec Interuniversitair Micro E | Bipolaire heterojunctie-transistor en werkwijze voor de vervaardiging daarvan. |
| US5035708A (en) * | 1985-06-06 | 1991-07-30 | Thomas Jefferson University | Endothelial cell procurement and deposition kit |
| GB8606468D0 (en) * | 1986-03-15 | 1986-04-23 | Sds Biotech Uk Ltd | Therapeutic compositions |
| US5010009A (en) * | 1988-08-22 | 1991-04-23 | Commonwealth Scientific & Industrial Research Organisation & Telectronics Pty. Limited | Material for cell attachment and growth |
| US5108436A (en) * | 1988-09-29 | 1992-04-28 | Collagen Corporation | Implant fixation |
| JPH0791181B2 (ja) * | 1989-12-26 | 1995-10-04 | 花王株式会社 | 浴用剤組成物 |
-
1992
- 1992-04-28 ZA ZA923086A patent/ZA923086B/xx unknown
- 1992-04-29 GB GB9209213A patent/GB2255907B/en not_active Expired - Fee Related
- 1992-04-29 US US07/875,368 patent/US5443531A/en not_active Expired - Fee Related
- 1992-04-29 FR FR9205249A patent/FR2675694A1/fr active Granted
- 1992-04-29 DE DE4214117A patent/DE4214117A1/de not_active Ceased
-
1994
- 1994-04-07 US US08/224,338 patent/US5769895A/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4627982A (en) * | 1984-07-16 | 1986-12-09 | Collagen Corporation | Partially purified bone-inducing factor |
| EP0271668A1 (de) * | 1986-10-22 | 1988-06-22 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Wachstumstimulierendes Material, Herstellungsverfahren und therapeutische Zusammensetzung |
| WO1989010409A1 (en) * | 1988-04-08 | 1989-11-02 | Genetics Institute, Inc. | Bone and cartilage inductive compositions |
| WO1990003733A1 (en) * | 1988-10-11 | 1990-04-19 | International Genetic Engineering, Inc. | Osteogenic factors |
| WO1990011366A1 (en) * | 1989-03-28 | 1990-10-04 | Genetics Institute, Inc. | Osteoinductive compositions |
| US7720174B2 (en) * | 2001-12-21 | 2010-05-18 | Digital Fountain, Inc. | Multi-stage code generator and decoder for communication systems |
Non-Patent Citations (3)
| Title |
|---|
| CLINICAL ORTHOPAEDICS AND RELATED RESEARCH no. 268, Juillet 1991, pages 303 - 312 Y.ORISAKA ET AL. * |
| PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 81, Janvier 1984, pages 371 - 375 M.R.URIST ET AL. * |
| PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 84, Octobre 1987, pages 7109 - 7113 T.K.SAMPATH ET AL. DISCUSSION * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0616814A1 (en) * | 1993-03-26 | 1994-09-28 | Bristol-Myers Squibb Company | Compositions for controlled release of biologically active TGF - beta |
| US8663337B2 (en) | 2007-06-18 | 2014-03-04 | Zimmer, Inc. | Process for forming a ceramic layer |
Also Published As
| Publication number | Publication date |
|---|---|
| DE4214117A1 (de) | 1992-11-05 |
| GB2255907A (en) | 1992-11-25 |
| ZA923086B (en) | 1993-10-28 |
| US5769895A (en) | 1998-06-23 |
| FR2675694B1 (enExample) | 1995-05-24 |
| GB2255907B (en) | 1994-12-14 |
| US5443531A (en) | 1995-08-22 |
| GB9209213D0 (en) | 1992-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2675694A1 (fr) | Systeme d'apport osteogenique pour facteurs de croissance morphogenetiques et procede pour preparer un tel systeme. | |
| Takaoka et al. | Ectopic bone induction on and in porous hydroxyapatite combined with collagen and bone morphogenetic protein | |
| EP0411105B1 (en) | Bone collagen matrix for implants | |
| EP0362367B1 (en) | Osteogenic devices | |
| KR0145278B1 (ko) | 골형성원 단백질 약제 | |
| CA2191584C (en) | Manufacture of autogenous replacement body parts | |
| US5162114A (en) | Bone collagen matrix for xenogenic implants | |
| JP4732587B2 (ja) | 骨形成ペースト組成物およびその用途 | |
| CA2094027C (en) | Osteogenic peptides | |
| US20050142164A1 (en) | Osteogenic device and a method for preparing the device | |
| US20030228345A1 (en) | Osteogenic devices | |
| JP2004262758A (ja) | 多孔性β−リン酸三カルシウム顆粒および同一のものを生成する方法 | |
| FR2564732A1 (fr) | Biomatiere osteoformatrice artificielle et son procede de fabrication | |
| JPH09505305A (ja) | 骨形成促進生成物および骨形成方法 | |
| WO1991005802A1 (en) | Osteogenic devices | |
| US10960109B2 (en) | Autologous bone graft substitute | |
| Ferretti et al. | Human segmental mandibular defects treated with naturally derived bone morphogenetic proteins | |
| Kamakura et al. | New scaffold for recombinant human bone morphogenetic protein‐2 | |
| US11596712B2 (en) | Autologous bone graft substitute composition | |
| Ripamonti | Calvarial regeneration in primates with autolyzed antigen-extracted allogeneic bone | |
| Won et al. | Clinical evaluation of demineralized bone allograft for sinus lifts in humans: a clinical and histologic study | |
| Wadhwa et al. | Microcomputed Tomography and Histological Study of Bone Regeneration Using Tooth Biomaterial with BMP‐2 in Rabbit Calvarial Defects | |
| Lee et al. | Effects of block bone substitutes loaded with Escherichia coli-produced recombinant human bone morphogenetic protein-2 on space maintenance and bone formation in rat calvarial onlay model | |
| Ripamonti | The Generation of Bone in Nonhuman Primates: Experimental Studies on the Baboon (Papio Ursinus) | |
| JPH0755235B2 (ja) | 骨形成用注入材料 |